Abstract 5103: The Dark Cancer Kinome—Untapped Opportunities for the…

Kinases are firmly established drug targets in cancer. There are currently 44 FDA-approved kinase drugs and hundreds of compounds are in clinical development. However, less than 10% of the Kinome is currently targeted and a large proportion is considered understudied by the NIH Illuminating the Druggable Genome Program (https://druggablegenome.net/). Read more “Abstract 5103: The Dark Cancer Kinome—Untapped Opportunities for the Development of Novel Drugs” →